Feb 7th 2023 - Mar 21st 2023
Data tells me no safety issues, with a possible la... See more
Then they dropped the “good” totally “not disappoi... See more
Feb 7th 2023 - Mar 21st 2023
$BCRX European stocks rose on Friday as investor... See more
#1 Suddenly alot of positive accounts appear, prom... See more
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 7th 2023 - Mar 21st 2023
See 20+ , low float , P/E ratio , EPS , positive data .
3.67 cash per share and $20+ PT's. Not to ment... See more
Data tells me no safety issues, with a possible large therapeutic window.
Then they dropped the “good” totally “not disappointing” data that Remi was so “Thrilled” about.
This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA
SAVA data gets analyzed by multiple different labs and shows its cognition improvement in mild AD cases, safe and well-tolerated
$SAVA I love not being able to hold $28 off data that will keep it pinned here until 2024.
but the data to date would predict continued efficacy that will be nigh on impossible to ignore.
Data teasing is very positive. 🚀
$SAVA Institutional buying says data is good!! !
I’ll keep buying until data comes out…
Excited for the next data unveiling….bring it on!
$BCRX European stocks rose on Friday as investors took an optimistic view of a week of data releases that showed economies in Europe and the US were more robust than expected.
#1 Suddenly alot of positive accounts appear, promoting the company has solid data, solid sales
$BCRX Have strong feeling once 10013 data is out we are going places.
P1 data is nice ,
The data looks good.
$BCRX This preliminary data on BCX10013 is pretty impressive.
$BCRX Good 10013 data.
10013 data looks good,
$BCRX great 10013 data and 320+ projected rev
but it also seems like the good choice to do so seeing iptacopan data.
See 20+ , low float , P/E ratio , EPS , positive data .
3.67 cash per share and $20+ PT's. Not to mention, consistency with positive studies and data.
$BXRX must be good phase 2 data
This is accurate up to date short data.
